Celiac disease (CD) results in enteropathy and malabsorption that can cause prandial insulin-glucose mismatch in patients with type 1 diabetes (T1D). This study leveraged continuous glucose monitoring (CGM) in children during the first year after T1D diagnosis to determine whether those with untreated CD have lower post-prandial glucose levels compared to those without CD. Children with T1D, positive CD serologies and biopsy-confirmed CD (CD+) were matched 1-to-4 to children with T1D but negative CD serologies (CD-) on age, sex, BMI and duration of diabetes. Meals were analyzed in the 30-day window before CD serologies and were computationally defined as paired CGM glucose peaks and troughs. Differences in the primary outcome, post-prandial trough, and other post-prandial glucose variables were assessed via log-linear mixed models. The cohort (N = 16 CD+, N = 64 CD-) was 69% female, with median age 10.7 years (interquartile range 8.9 - 12.8), T1D duration 4.1 months (2.3 - 7.7), and BMI z-score 0.29 (0.00 - 0.92). Over the 30-day window, mean post-prandial trough glucose and peak glucose were 111.7 mg/dL (SD 36.3) and 213.6 mg/dL (48.5) in the CD+ children, and 128.6 mg/dL (39.8) and 238.4 mg/dL (53.0) in the CD- children, respectively. In the repeated measures models, CD diagnosis reduced trough glucose by 12.8% (p = 0.059) and reduced peak glucose by 10.2% (p = 0.048). Other secondary outcomes including change in glucose or time from peak to trough did not significantly differ between groups. There is a quantifiable difference in post-prandial glucose when CD is present and untreated in patients with T1D. These findings can inform a future, CGM-based, predictive model of CD in T1D to prompt screening and aid in earlier diagnosis and treatment.

Disclosure

J. Ruiz: Research Support; Dexcom, Inc. L. Asaro: None. A. Bernique: None. S. Clemons: None. J.A. Silvester: Consultant; Takeda Pharmaceutical Company Limited. Research Support; Takeda Pharmaceutical Company Limited. Other Relationship; Wolters Kluwer Health. D. Wypij: None. M. Agus: Research Support; Dexcom, Inc.

Funding

Cystic Fibrosis Foundation ù Pediatric Scientist Development Program (K12-HD000850)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.